Loading...
XSHE
002022
Market cap475mUSD
Dec 05, Last price  
6.58CNY
1D
0.46%
1Q
-2.08%
Jan 2017
-67.10%
IPO
320.45%
Name

Shanghai Kehua Bio-Engineering Co Ltd

Chart & Performance

D1W1MN
XSHE:002022 chart
P/E
P/S
1.91
EPS
Div Yield, %
Shrs. gr., 5y
-0.32%
Rev. gr., 5y
-6.14%
Revenues
1.76b
-27.11%
300,565,543339,115,594399,096,017487,116,254621,196,340781,315,791873,890,4421,013,681,3211,114,434,6311,217,885,7331,155,783,3431,396,672,0881,594,116,2121,990,213,5582,414,471,2894,155,428,8464,854,310,5236,969,862,6272,413,526,1421,759,197,330
Net income
-641m
L+173.74%
56,427,52074,576,211117,997,267166,075,707204,342,546225,258,510226,748,967239,830,021288,329,176291,973,949210,624,935232,400,489217,759,949207,778,849273,394,3561,142,202,5711,353,824,7601,731,370,056-234,014,886-640,601,876
CFO
-50m
L-89.45%
73,970,50487,211,768112,932,259137,662,631217,508,063241,827,895219,800,208213,743,675250,221,961249,638,498224,298,097281,252,696130,713,194126,790,596248,872,0341,367,198,2501,079,220,2642,153,632,187-474,894,786-50,115,999
Dividend
May 10, 20230.6 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Shanghai Kehua Bio-Engineering Co.,Ltd researches and develops, produces, and sells in vitro diagnostic products in China. The company offers HBV, hepatitis B, HCV antibody, alpha fetoprotein quantitative, and fecal occult blood test kits; carcino-embryonic antigen quantitative determination kits; test kits for antibody to treponema pallidum and human immunodeficiency virus, and the five serological markers of hepatitis B; and diagnostic kit for syphilis rapid plasma regain. It also provides automatic biochemical analysis systems for clinical laboratories and medical institutions; nucleic acid blood screening systems; automatic chemiluminescence measuring systems; microplate readers and plate washers; general and dedicated reagent packaging systems; and electrolyte analyzers. In addition, the company researches and develops diagnostic products in the field of renal disease that provides screening diagnosis and therapeutic effect monitoring solutions for patients with various types of kidney disease. Further, it offers single-part and multi-part nucleic acid detection, and enzyme immunoassay analysis systems; reagents for blood collection agencies and clinical diagnosis; and laboratory diagnostic instruments. Additionally, the company distributes automatic chemiluminescence, microbial, and blood and urine analysis systems, as well as their supporting supplies; and automatic biochemical analyzers and other products. It also establishes third-party medical laboratory centers; provides planning and designing, management consulting, equipment and reagent supplying, and supply chain optimization services for medical laboratories, as well as medical testing services. In addition, the company is involved in the social medical undertakings. It also exports its Kehua-branded products to 38 countries and regions. The company was founded in 1981 and is based in Shanghai, the People's Republic of China.
IPO date
Jul 21, 2004
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT